#USA #Lexington, KY #Piramal Pharma #Lexington KY #Microbiology Lab

Piramal Pharma Solutions Expands Microbiology Laboratory in Lexington, Kentucky

Piramal Pharma Solutions (PPS), a prominent Contract Development and Manufacturing Organization (CDMO) under Piramal Pharma Ltd., has made significant strides in bolstering its laboratory capabilities with the inauguration of a new microbiology laboratory at its sterile injectable production facility in Lexington, Kentucky. This new addition is part of a larger $85 million expansion project aimed at enhancing the site’s commercial-scale production capabilities and overall operational efficiency.

The microbiology lab was approved for routine Good Manufacturing Practice (GMP) use on September 11, 2026, and soon received conditional approval for its new sterility testing suite. This relatively quick timeline underscores the lab's importance as one of the initial significant components to come online during the ongoing expansion, which is set to be fully operational by late 2027.

Enhanced Laboratory Capabilities

The newly established microbiology laboratory significantly expands the existing testing space, more than tripling its previous size. This increase allows for enhanced laboratory workflow and the capacity to accommodate future growth in microbiological testing. With this new setup, Piramal is better positioned to run concurrent tests, thanks to the addition of three new biosafety cabinets, thereby shortening sample queue times.

All incubators have now been consolidated within the new laboratory, promoting a more streamlined workflow and better monitoring of test activities. A key feature of this new lab is its dedicated sterility testing suite, which boasts a Grade C background environment, marking a substantial upgrade from the previously unclassified area.

At the heart of the testing suite is a fully integrated, Grade A sterility testing isolator, which doubles the site’s testing capacity while allowing multiple samples to be processed simultaneously. The new isolator supports both open and closed filtration methods, granting greater flexibility and ensuring a wider range of product testing capabilities.

Accelerating Testing Processes

Incorporating built-in pass-throughs enables samples to be transferred directly from the manufacturing floor to the laboratory, significantly reducing contamination risk and preserving product integrity. These enhancements are projected to cut testing times by up to 50%, thereby expediting batch releases, reducing bottlenecks, and ensuring smoother transitions as products progress from clinical to commercial stages.

Furthermore, the upgraded infrastructure strengthens the site's contamination control and sterility assurance capabilities. With the additional capacity, Piramal is now better equipped to manage supply risks and meet increasing commercial-scale demand. Nathan Richardson, Vice President and Site Head of Piramal Pharma Solutions in Lexington, highlighted the milestone, stating, "The new microbiology laboratory marks an important chapter in our Lexington expansion journey. It enhances our sterility testing and microbiological quality capabilities, further solidifying our commitment to operational excellence and patient safety."

Supporting a Global Client Base

The launch of the new microbiology lab not only reinforces Piramal’s leadership position in the sterile injectables market but also empowers the Lexington facility to provide high-quality, reliable, and patient-focused services to clients across various modalities, including small molecules, bioconjugates, and peptides.

Piramal Pharma Solutions continues to demonstrate its dedication to operational excellence and growth in sterile injectable manufacturing in Lexington, ensuring that it can meet the evolving needs of its clients.

For more information about Piramal Pharma Solutions and its suite of services, visit their official website or connect with them on LinkedIn, Facebook, and X.